TREMs in Alzheimer's disease: Genetic and clinical investigations

Clinica Chimica Acta

Volumn 463, Issue , 2016, Pages 88-95

  Cheng, Jia ^a   Guo, XiaoFeng ^a   Zhang, Tian ^a   Zhong, Li ^a   Bu, GuoJun ^a,b   Chen, XiaoFen ^a  

^a XIAMEN UNIVERSITY   (China)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Alzheimer's disease; Biomarker; Epigenetic; sTREM2; TREM2; TREML

Indexed keywords

TAU PROTEIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; TREM2 PROTEIN, HUMAN;

AFRICAN AMERICAN; ALZHEIMER DISEASE; CANADIAN; CASE CONTROL STUDY; CAUCASIAN; CEREBROSPINAL FLUID; CHINESE; DISEASE COURSE; EUROPEAN; EXON; GENE; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IRANIAN PEOPLE; JAPANESE (PEOPLE); KOREAN (PEOPLE); NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREM1 GENE; TREM2 GENE; TREML GENE; BONE MARROW CELL; GENETICS; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; HUMANS; MEMBRANE GLYCOPROTEINS; MYELOID CELLS; RECEPTORS, IMMUNOLOGIC;

EID: 84992156994     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.10.022     Document Type: Review

References (67)

1. [1] Pelham, C.J., Pandya, A.N., Agrawal, D.K., Triggering receptor expressed on myeloid cells receptor family modulators: a patent review. Expert Opin. Ther. Pat. 24 (2014), 1383–1395.
2. [2] Colonna, M., TREMs in the immune system and beyond. Nat. Rev. Immunol. 3 (2003), 445–453.
3. [3] Painter, M.M., Atagi, Y., Liu, C.C., et al. TREM2 in CNS homeostasis and neurodegenerative disease. Mol. Neurodegener., 10, 2015, 43.
4. [4] Ford, J.W., McVicar, D.W., TREM and TREM-like receptors in inflammation and disease. Curr. Opin. Immunol. 21 (2009), 38–46.
5. [5] Burns, A., Iliffe, S., Alzheimer's disease. Br. Med. J., 338, 2009, b158.
6. [6] Liu, G., Liu, Y., Jiang, Q., et al. Convergent genetic and expression datasets highlight TREM2 in Parkinson's disease susceptibility. Mol. Neurobiol., 2015.
7. [7] Bailey, R.M., Howard, J., Knight, J., Sahara, N., Dickson, D.W., Lewis, J., Effects of the C57BL/6 strain background on tauopathy progression in the rTg4510 mouse model. Mol. Neurodegener., 9, 2014, 8.
8. [8] Ulrich, J.D., Finn, M.B., Wang, Y., et al. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol. Neurodegener., 9, 2014, 20.
9. [9] Lill, C.M., Rengmark, A., Pihlstrom, L., et al. The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimers Dement., 2015.
10. [10] Ma, J., Zhou, Y., Xu, J., et al. Association study of TREM2 polymorphism rs75932628 with late-onset Alzheimer's disease in Chinese Han population. Neurol. Res. 36 (2014), 894–896.
11. [11] Jiao, B., Liu, X., Tang, B., et al. Investigation of TREM2, PLD3, and UNC5C variants in patients with Alzheimer's disease from mainland China. Neurobiol. Aging, 35, 2014 (2422.e2429-2422.e2411).
12. [12] Yu, J.T., Jiang, T., Wang, Y.L., et al. Triggering receptor expressed on myeloid cells 2 variant is rare in late-onset Alzheimer's disease in Han Chinese individuals. Neurobiol. Aging 35 (2014), 937.e931–937.e933.
13. [13] Miyashita, A., Wen, Y., Kitamura, N., et al. Lack of genetic association between TREM2 and late-onset Alzheimer's disease in a Japanese population. J. Alzheimers Dis. 41 (2014), 1031–1038.
14. [14] Chung, S.J., Kim, M.J., Kim, J., et al. Exome array study did not identify novel variants in Alzheimer's disease. Neurobiol. Aging, 35, 2014, 1958, e1913-1954.
15. [15] Huang, M., Wang, D., Xu, Z., et al. Lack of genetic association between TREM2 and Alzheimer's disease in east Asian population: a systematic review and meta-analysis. Am. J. Alzheimers Dis. Other Demen. 30 (2015), 541–546.
16. [16] Mehrjoo, Z., Najmabadi, A., Abedini, S.S., et al. Association study of the TREM2 Gene and Identification of a novel variant in exon 2 in Iranian patients with late-onset Alzheimer's disease. Med. Princ. Pract. 24 (2015), 351–354.
17. [17] Jin, S.C., Carrasquillo, M.M., Benitez, B.A., et al. TREM2 is associated with increased risk for Alzheimer's disease in African Americans. Mol. Neurodegener., 10, 2015, 19.
18. [18] Cruchaga, C., Kauwe, J.S., Harari, O., et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron 78 (2013), 256–268.
19. [19] Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 45 (2013), 1452–1458.
20. [20] Benitez, B.A., Jin, S.C., Guerreiro, R., et al. Missense variant in TREML2 protects against Alzheimer's disease. Neurobiol. Aging 35 (2014), 1510.e1519–1510.e1526.
21. [21] Replogle, J.M., Chan, G., White, C.C., et al. A TREM1 variant alters the accumulation of Alzheimer-related amyloid pathology. Ann. Neurol. 77 (2015), 469–477.
22. [22] Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med., 6, 2014 (243ra286).
23. [23] Heslegrave, A., Heywood, W., Paterson, R., et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol. Neurodegener., 11, 2016, 3.
24. [24] Suárez-Calvet, M., Kleinberger, G., Araque Caballero, M.A., et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol. Med., 2016.
25. [25] Piccio, L., Deming, Y., Del-Aguila, J.L., et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol., 2016.
26. [26] Benitez, B.A., Cooper, B., Pastor, P., et al. TREM2 is associated with the risk of Alzheimer's disease in Spanish population. Neurobiol. Aging(34), 2013 (1711.e1715-1717.
27. [27] Borroni, B., Ferrari, F., Galimberti, D., et al. Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol. Aging, 35, 2014 (934.e937-910).
28. [28] Cuyvers, E., Bettens, K., Philtjens, S., et al. Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol. Aging, 35, 2014 (726.e711-729).
29. [29] Finelli, D., Rollinson, S., Harris, J., et al. TREM2 analysis and increased risk of Alzheimer's disease. Neurobiol. Aging, 36, 2015 (546.e549-513).
30. [30] Gonzalez Murcia, J.D., Schmutz, C., Munger, C., et al. Assessment of TREM2 rs75932628 association with Alzheimer's disease in a population-based sample: the Cache County Study. Neurobiol. Aging, 34, 2013 2889.e2811-2883.
31. [31] Giraldo, M., Lopera, F., Siniard, A.L., et al. Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease. Neurobiol. Aging, 2077(34), 2013, e2011-2078.
32. [32] Guerreiro, R., Wojtas, A., Bras, J., et al. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368 (2013), 117–127.
33. [33] Jin, S.C., Benitez, B.A., Karch, C.M., et al. Coding variants in TREM2 increase risk for Alzheimer's disease. Hum. Mol. Genet. 23 (2014), 5838–5846.
34. [34] Jonsson, T., Stefansson, H., Steinberg, S., et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368 (2013), 107–116.
35. [35] Pottier, C., Wallon, D., Rousseau, S., et al. TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. J. Alzheimers Dis. 35 (2013), 45–49.
36. [36] Rosenthal, S.L., Bamne, M.N., Wang, X., et al. More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk. Neurobiol. Aging 36 (2015), 2443.e2421–2443.e2446.
37. [37] Roussos, P., Katsel, P., Fam, P., Tan, W., Purohit, D.P., Haroutunian, V., The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia. Alzheimers Dement. 11 (2015), 1163–1170.
38. [38] Ruiz, A., Dols-Icardo, O., Bullido, M.J., et al. Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. Neurobiol. Aging, 35, 2014 (444.e441-444).
39. [39] Slattery, C.F., Beck, J.A., Harper, L., et al. R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimers Dement. 10 (2014), 602–608, e604.
40. [40] Jiang, T., Tan, L., Chen, Q., et al. A rare coding variant in TREM2 increases risk for Alzheimer's disease in Han Chinese. Neurobiol. Aging, 42, 2016, 217, e211-213.
41. [41] Ghani, M., Sato, C., Kakhki, E.G., et al. Mutation analysis of the MS4A and TREM gene clusters in a case-control Alzheimer's disease data set. Neurobiol. Aging, 42, 2016, 217, e217-217 e213.
42. [42] Malik, M., Parikh, I., Vasquez, J.B., et al. Genetics ignite focus on microglial inflammation in Alzheimer's disease. Mol. Neurodegener., 10, 2015, 52.
43. [43] Wilson, R.S., Barral, S., Lee, J.H., et al. Heritability of different forms of memory in the late onset Alzheimer's disease family study. J. Alzheimers Dis. 23 (2011), 249–255.
44. [44] Forabosco, P., Ramasamy, A., Trabzuni, D., et al. Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol. Aging 34 (2013), 2699–2714.
45. [45] Jiang, T., Wan, Y., Zhang, Y.D., et al. TREM2 overexpression has no improvement on neuropathology and cognitive impairment in aging APPswe/PS1dE9 mice. Mol. Neurobiol., 2016.
46. [46] Jiang, T., Tan, L., Zhu, X.C., et al. Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer's disease. Neuropsychopharmacology 39 (2014), 2949–2962.
47. [47] Xiang, X., Werner, G., Bohrmann, B., et al. TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol. Med. 8 (2016), 992–1004.
48. [48] Jiang, T., Tan, L., Zhu, X.C., et al. Silencing of TREM2 exacerbates tau pathology, neurodegenerative changes, and spatial learning deficits in P301S tau transgenic mice. Neurobiol. Aging 36 (2015), 3176–3186.
49. [49] Frost, B., Gotz, J., Feany, M.B., Connecting the dots between tau dysfunction and neurodegeneration. Trends Cell Biol. 25 (2015), 46–53.
50. [50] Jiang, T., Zhang, Y.D., Chen, Q., et al. TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice. Neuropharmacology 105 (2016), 196–206.
51. [51] Tang, Y., Le, W., Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol. Neurobiol. 53 (2016), 1181–1194.
52. [52] Barber, R.C., Phillips, N.R., Tilson, J.L., et al. Can genetic analysis of putative blood Alzheimer's disease biomarkers lead to identification of susceptibility loci?. PLoS One, 10, 2015, e0142360.
53. [53] Zhao, Y., Jaber, V., Lukiw, W.J., Over-expressed pathogenic miRNAs in Alzheimer's disease (AD) and Prion disease (PrD) drive deficits in TREM2-mediated Abeta42 peptide clearance. Front. Aging Neurosci., 8, 2016, 140.
54. [54] Celarain, N., de Gordoa J, S.-R., Zelaya, M.V., et al. TREM2 upregulation correlates with 5-hydroxymethycytosine enrichment in Alzheimer's disease hippocampus. Clin. Epigenetics, 8(37), 2016.
55. [55] Smith, A.R., Smith, R.G., Condliffe, D., et al. Increased DNA methylation near TREM2 is consistently seen in the superior temporal gyrus in Alzheimer's disease brain. Neurobiol. Aging 47 (2016), 35–40.
56. [56] Lue, L.F., Schmitz, C.T., Serrano, G., Sue, L.I., Beach, T.G., Walker, D.G., TREM2 protein expression changes correlate with Alzheimer's disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Pathol. 25 (2015), 469–480.
57. [57] Mori, Y., Yoshino, Y., Ochi, S., et al. TREM2 mRNA expression in leukocytes is increased in Alzheimer's disease and schizophrenia. PLoS One, 10, 2015, e0136835.
58. [58] Matarin, M., Salih, D.A., Yasvoina, M., et al. A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep. 10 (2015), 633–644.
59. [59] Gispert, J.D., Suárez-Calvet, M., Monte, G.C., et al. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. Alzheimers Dement., 2016.
60. [60] Henjum, K., Almdahl, I.S., Arskog, V., et al. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. Alzheimers Res. Ther., 8, 2016, 17.
61. [61] Yamada, K., Patel, T.K., Hochgrafe, K., et al. Analysis of in vivo turnover of tau in a mouse model of tauopathy. Mol. Neurodegener., 10, 2015, 55.
62. [62] Song, W., Hooli, B., Mullin, K., et al. Alzheimer's disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimers Dement., 2016.
63. [63] Sirkis, D.W., Bonham, L.W., Aparicio, R.E., et al. Rare TREM2 variants associated with Alzheimer's disease display reduced cell surface expression. Acta Neuropathol. Commun., 4, 2016, 98.
64. [64] Atagi, Y., Liu, C.C., Painter, M.M., et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J. Biol. Chem. 290 (2015), 26043–26050.
65. [65] Bailey, C.C., DeVaux, L.B., Farzan, M., The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J. Biol. Chem. 290 (2015), 26033–26042.
66. [66] Yeh, F.L., Wang, Y., Tom, I., Gonzalez, L.C., Sheng, M., TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-Beta by microglia. Neuron 91 (2016), 328–340.
67. [67] Graham, L.C., Harder, J.M., Soto, I., de Vries, W.N., John, S.W., Howell, G.R., Chronic consumption of a western diet induces robust glial activation in aging mice and in a mouse model of Alzheimer's disease. Sci. Rep., 6, 2016, 21568.